UY33279A - Una pirimidina sustituida como un antagonista del receptor de la prostaglandina d2 - Google Patents

Una pirimidina sustituida como un antagonista del receptor de la prostaglandina d2

Info

Publication number
UY33279A
UY33279A UY0001033279A UY33279A UY33279A UY 33279 A UY33279 A UY 33279A UY 0001033279 A UY0001033279 A UY 0001033279A UY 33279 A UY33279 A UY 33279A UY 33279 A UY33279 A UY 33279A
Authority
UY
Uruguay
Prior art keywords
prostaglandina
antagonist
receiver
compound
pyrimidine
Prior art date
Application number
UY0001033279A
Other languages
English (en)
Inventor
Gregory B Poli
Zhao Zhicheng
Joacy C Aguiar
Yong-Mi Choi-Sledeski
Keith J Harris
Patrick Wai-Kwok Shum
Stoklosa Gregory
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of UY33279A publication Critical patent/UY33279A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente invención se refiere a un compuesto de amino-piridina 2,6-sustituida-4-monosustituida de la fórmula (I) o un enantiómero del mismo, o un profármaco éster o una sal del mismo farmacéuticamente aceptable, o una composición farmacéutica que comprende un compuesto de este tipo . La invención incluye también un método de tratamiento de un paciente mediante la administración de una cantidad farmacéuticamente eficaz de un compuesto de este tipo.
UY0001033279A 2010-03-16 2011-03-16 Una pirimidina sustituida como un antagonista del receptor de la prostaglandina d2 UY33279A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31442110P 2010-03-16 2010-03-16

Publications (1)

Publication Number Publication Date
UY33279A true UY33279A (es) 2011-10-31

Family

ID=43991061

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033279A UY33279A (es) 2010-03-16 2011-03-16 Una pirimidina sustituida como un antagonista del receptor de la prostaglandina d2

Country Status (15)

Country Link
US (1) US20130005741A1 (es)
EP (1) EP2547673A1 (es)
JP (1) JP2013522307A (es)
KR (1) KR20130008043A (es)
CN (1) CN103025726A (es)
AR (1) AR080527A1 (es)
AU (1) AU2011227420A1 (es)
BR (1) BR112012023039A2 (es)
CA (1) CA2793324A1 (es)
MX (1) MX2012010038A (es)
RU (1) RU2012143978A (es)
SG (1) SG183531A1 (es)
TW (1) TW201204708A (es)
UY (1) UY33279A (es)
WO (1) WO2011115943A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR088204A1 (es) * 2011-09-29 2014-05-14 Shionogi & Co Medicamentos para el tratamiento de la rinitis alergica que comprenden un antagonista de pgd2 y un antagonista de histamina
US9797903B2 (en) 2012-10-24 2017-10-24 Winthrop-University Hospital Non-invasive biomarker to identify subject at risk of preterm delivery
US10246462B2 (en) 2016-09-09 2019-04-02 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
AU2018331400A1 (en) 2017-09-13 2020-04-02 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2291157A1 (en) 1997-05-29 1998-12-03 Eli Lilly And Company Process for preparing heterocyclic compounds
WO2000071519A2 (en) 1999-05-21 2000-11-30 Eli Lilly And Company Immunopotentiator agents
EP1274457B1 (en) 2000-04-12 2005-11-30 Merck Frosst Canada & Co. Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
AR060403A1 (es) * 2006-04-12 2008-06-11 Sanofi Aventis Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2
WO2008039882A1 (en) * 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist

Also Published As

Publication number Publication date
AU2011227420A1 (en) 2012-10-04
CA2793324A1 (en) 2011-09-22
RU2012143978A (ru) 2014-04-27
EP2547673A1 (en) 2013-01-23
TW201204708A (en) 2012-02-01
KR20130008043A (ko) 2013-01-21
US20130005741A1 (en) 2013-01-03
CN103025726A (zh) 2013-04-03
AR080527A1 (es) 2012-04-11
MX2012010038A (es) 2012-10-01
SG183531A1 (en) 2012-10-30
WO2011115943A1 (en) 2011-09-22
JP2013522307A (ja) 2013-06-13
BR112012023039A2 (pt) 2016-05-17

Similar Documents

Publication Publication Date Title
UY33278A (es) Pirimidinas sustituidas como antagonistas del receptor de la protaglandina d2
PH12018500147A1 (en) Benzodiazepine derivatives as rsv inhibitors
NI201200168A (es) Formulaciones farmacéuticas
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MD20140136A2 (ro) Inhibitori ai virusului hepatic C
PE20150887A1 (es) Compuestos de benceno sustituidos
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
IN2014CN04907A (es)
UY32490A (es) Inhibidores de beta-secretasa
IN2014CN00989A (es)
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
CO7131360A2 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
MX370141B (es) Profármacos que comprenden un conjugado de ácido hialurónico enlazador agonista dual de glp-1/glucagón.
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
TN2011000585A1 (en) Lxr modulators
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
WO2012040636A3 (en) Compounds and methods for treating diseases mediated by protease activated receptors
UY33279A (es) Una pirimidina sustituida como un antagonista del receptor de la prostaglandina d2
MX362919B (es) Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1].
UY35209A (es) Compuestos tricíclicos
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
MX2014000855A (es) Moduladores receptores de glucagon de quinolinilo.
EA201600411A1 (ru) Производные пиперидина для применения при лечении или профилактики психиатрических и неврологических состояний

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20191217